Antibody-Drug Conjugates 2

• 6920 · PDF Preclinical development of a first-in-class CD64-ADC to target leukemic monocytes and tumor-associated macrophages Lia Buffa, Cintia Garro, Constanza Marin, Alejandra Garcia, Diego Andino, Melisa Capitanelli, Laura Bertoldi, Florencia Villafanez, Natalia Monjes, Agustina Garcia-Melani, Laura Guantay, Daniela Arroyo, Alejandro Moyano, Gimena Ferreira, Belkys Marelli, Tarek Zaki, Gerardo Gatti, Candelaria Llorens de los Rios, Gaston Soria
• 6921 · PDF Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vgamma9Vdelta2 T cells leading to selective tumor cell killing Mary J. van Helden, Genny Filliciotto, Wendela A. Kappers, Diels van den Dobbelsteen, Panagiota I. Spantidea, Marga Gunnewijk, Myrthe Rouwette, Anja Scholzen, Seline A. Zwarthoff, Stefanie J. J. Bartels, Sebastiaan Birkedal, Sanne H. C. van den Ouweland, Ellen W. H. Santegoeds-Lenssen, Robbin Tebes, Menno Winkel, Marc C. B. Parade, Lilian Driessen-Engels, Karin de Laat-Arts, Ivan Faraho, Inge M. J. Reinieren-Beeren, Giel Verhagen, Dorian van Kuijk, Daphne W. J. van Kuppeveld, Benny de Wit, Gijs Verheijden, Ruud Ubink, Benno Ingelse, Miranda M. C. Van der Lee, Wim H. A. Dokter
• 6922 · PDF BHB810: A novel site-specific CDH17-directed VHH-Fc ADC for gastric cancer Ryan Henrici, Timothy Park, Melanie Montgomery, Barbara Steurer, Danielle Barreras, Natalie Alba, Srujan Vadlamudi, Hunter Elliott, Jon Wojciak, John Corbin, Peyton Greenside
• 6923 · PDF Targeting tumor-specific Tn-glycoforms of MUC1 and MUC4 with first-in-class antibody-drug conjugates: Preclinical efficacy and translational potential of GO-M100B and GO-M400 Nisha Shrestha, Aaron Christopher Groen, Boris Klebanov, Constantine Theodoropulos, Hans H. Wandall
• 6925 · PDF Leveraging AI-enhanced multi-omics discovery of novel tumor-selective targets for ADC development Daniel Montoro, Christoph Muus, Karthik Jagadeesh, Cecile Rouleau, Yueyue Shi, Sho Takahashi, James Meador, Ritika Singh
• 6926 · PDF An AI-guided biparatopic DLL3-targeting ADC demonstrates enhanced preclinical efficacy Chuan Chen, Yue Wu, Chenpeng Su, Zhaohui Chen, Dandan Liu, Jiyuan Tian, Xiaoqian Chen, Yang He, Yongxin Shang, Rongmei Yan, Liang Tian, Jian Peng, Zhenping Zhu
• 6927 · PDF ADCE-T02 - A clinical stage antibody drug conjugate targeting tissue factor demonstrates strong efficacy in preclinical models of head and neck squamous cell carcinoma Thomas Tuxen Poulsen, Olga Ilina, Pernille Barkholt, Daniela Pontieri, Jette Bomholt Lange, Jonathan Henry Wardman, Christophe Côme, Christina Hjæresen, Shu-Hui Liu, Xun Meng, Yue Zhang, Dominik Mumberg
• 6928 · PDF Dual-payload antibody drug conjugate targeting TROP2: Multi-Payload Conjugates™ targeting orthogonal mechanisms of cell killing Marco Lobba, Samantha Brady, Devin Trinter, Maxwell Nguyen, Chanez Symister, Andrew Lau, Derek Garcia-Almedina, Charlotte Choi, Saurabh Johri, Matthew Francis, Richard Kendall
• 6929 · PDF Targeting intracellular KRAS G12D /HLA-A11 pMHC with a novel TCR-mimic antibody-drug conjugate (TCRm-ADC) demonstrates potent antitumor activity in preclinical models Chia-Chun Chao, Wei-Ze Hong, Hsin-Yu Chang, Jhen-Yu Chen, Yi-Wen Jiang, K.S. Clifford Chao, Kevin Chih-Yang Huang
• 6930 · PDF Preclinical efficacy of BCG018, an ADC targeting ITGB6 and incorporating a topoisomerase I inhibitor payload, was demonstrated to be effective in PDX models Yi Yang, Mengran Li, Chengzhang Shang
• 6931 · PDF Preclinical study of BCG044, a novel bispecific ADC targeting EpCAM and HER3 for the treatment of colorectal and other tumors Jeremy Lee, Zhuolin Li, Chengzhang Shang, Yi Yang
• 6932 · PDF BCG045: A first-in-class bispecific ADC targeting TROP2 and MUC1 demonstrates promising tumor efficacy and potentially reduced toxicity in preclinical studies Jeremy Lee, Yifu Zhang, Chengzhang Shang, Yi Yang
• 6933 · PDF GQ1035: First-in-class ADC against novel targets for gastric cancer and ovarian cancer discovered via high-throughput screening​ Shanshan Xie, Meijun Xiong, Lina Wang, Yajun Sun, Chong Liu, Zhongsheng Hu, Xinju Gao, Yanwen Feng, Yu Han, Zengyan Mu, Paul H. Song, Gang Qin
• 6934 · PDF Integrated evaluation of payload-, Fc-, and target-mediated mechanisms of ADCs using streamlined complementary platforms Alpana Prasad, Surekha Bonasu, Radhika Venkatnarayanan, Jennifer Lin-Jones, Jane E. Lamerdin, Gaurav Agrawal, Nguyen Ly, Jesus A. Diaz de Leon, Venkatesh Chari
• 6935 · PDF BCG029: An ADAM9-Targeting ADC Featuring a Novel Topoisomerase I Inhibitor Payload Demonstrated Potent Efficacy in PDX Models Yong Xie, Mengran Li, Chengzhang Shang, Yi Yang
• 6936 · PDF A novel MSLN×CDH3 bispecific antibody-drug conjugate (BsADC) demonstrates promising anti-tumor efficacy Haochen Wei, Zihao Wang, Weiqiu Lan, Xi Yang, Kunying Hao, Jinhua Zhao, Yang Chen, Baihong Liu, Chengzhang Shang, Yi Yang
• 6937 · PDF BCG046, a CDCP1 ADC that targets CTF, has demonstrated potent in vitro and in vivo efficacy Haochen Wei, Na Zhang, Chengzhang Shang, Yi Yang
• 6938 · PDF BCG026: FAP × GPC1 bispecific ADC - A novel targeting approach for stromal and tumor cells in pancreatic cancer and other solid tumors Haochen Wei, Na Zhang, Kunying Hao, Chengzhang Shang, Yi Yang
• 6939 · PDF Tri-specific ADC platform offers potential therapeutic advantage over bi-specific ADC Yang Wang, Lixia Cao, Cui Feng, Fangdun Jiang, lixia Gu, Chen Li, Yifan Yang, Qi Zhang, Ming Zhou, Cancan Li, Wei Huang, Bonan Yan, Ziping Wei, Yuhong Zhou
• 6940 · PDF A first-in-class PD-L1/B7-H3/VEGF tri-specific ADC achieves enhanced preclinical antitumor efficacy through direct cytotoxicity, immune checkpoint blockade and VEGF inhibition Jiajia Pan, Pengfei Wang, Hongwang He, Mengfan Peng, Meng Cheng, Jie Zhang, Chengyi Ju, Jun Wang, Li Li, Hui Feng
• 6941 · PDF Bi- and tri-specific ADCs that target two distinct growth factor receptor forms of MUC1* and HER2 or alpha-v-beta-6 inhibit tumor recurrence and overcome acquired resistance Cynthia Carol Bamdad, Benoit J. Smagghe, Scott Moe, Mark G. Carter, Kevin R. Yi, Michael J. Nash, Robert McDermott, Trevor J. Grant, Salvatore Marchese, Daniel S. Miller, Natalie K. Miller, Andrew K. Stewart
• 6942 · PDF Validation of HER2, TROP2, and NECTIN4 IHC prediction algorithms for the ADC MATCH trial Kyle A. Beauchamp, Elizabeth Mauer, Kaveri Nadhamuni, Elizabeth morency, Alia Zander, Xingyu Zheng, Katherine Mclean, Sayantoni Mukhopadhyay, Seung Won Hyun, Chithra Sangli, Kate Sasser, Halla Nimeiri, Charles Koyias, Michelle Ting-Lin, Funda Meric-Bernstam
• 6943 · PDF Bispecific antibody with dual-payload ADC for metastatic castration-resistant prostate cancer Wenkai Zhao, Xiaofei Zhou, Ting Wang, Furong Guo, Huijie Zhao, Ning Wang, Teddy Yang, Ying Lei, Li Tong, Fei Peng
• 6944 · PDF Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity Zhaojun An, Jia Ge, Zhiqiang Xu, Yuhao Wang, Barry Duplantis, Quan Yu, Xiangyu He, Yi Li
• 6945 · PDF HDM2024: A novel EGFR and HER3 bispecific antibody-drug conjugate exhibits superior antitumor activity and favorable toxicological profile Qingyu Shu, Yan Xia, Zhaofeng Qin, Shengxing Zhao, Yang Chen, Rongrong He, Hao Pan, Hongwen Li, Dongzhou Jeffrey Liu
• 6946 · PDF Preclinical evaluation of BCG017, a novel bispecific ADC targeting PTK7 and EGFR Zipeng Zeng, Na Zhang, Chengzhang Shang, Yi Yang
• 6947 · PDF A novel bispecific antibody-drug conjugate, BCG016, that targets 5T4 and MUC1, demonstrates robust preclinical antitumor activity Zipeng Zeng, Yangyang Xu, Chengzhang Shang, Yi Yang
• 6948 · PDF A novel bispecific antibody-drug conjugate targeting CEACAM5 and CDH17 exhibits potent anti-tumor activity and enhanced tumor-selectivity Jinxiu Hou, Tingting Gu, Lisha Dong, Jiyuan Tian, Xiaoqian Chen, Dandan Liu, Yongxin Shang, Rongmei Yan, Kezhen Ye, Liang Tian, Jian Peng, Zhenping Zhu
• 6949 · PDF A novel multi-modal PD-L1-ADC could be a potential BIC candidate treatment for pan-solid tumors with enhanced tumor-specificity Tao Yang, Hang Ke, Feiyu Peng, Jialin Li, Cen Chen, Lei Zhang, Faming Zhang, Henry Li

在完整检索应用中浏览本分会场 →